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Abstract
Apoptotic cells release ‘find-me’ signals at the earliest stages of death to recruit phagocytes1. The
nucleotides ATP and UTP represent one class of find-me signals2, but their mechanism of release
is not known. Here, we identify the plasma membrane channel pannexin 1 (PANX1) as a mediator
of find-me signal/nucleotide release from apoptotic cells. Pharmacological inhibition and siRNA-
mediated knockdown of PANX1 led to decreased nucleotide release and monocyte recruitment by
apoptotic cells. Conversely, PANX1 over-expression enhanced nucleotide release from apoptotic
cells and phagocyte recruitment. Patch-clamp recordings showed that PANX1 was basally
inactive, and that induction of PANX1 currents occurred only during apoptosis. Mechanistically,
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PANX1 itself was a target of effector caspases (caspases 3 and 7), and a specific caspase-cleavage
site within PANX1 was essential for PANX1 function during apoptosis. Expression of truncated
PANX1 (at the putative caspase cleavage site) resulted in a constitutively open channel. PANX1
was also important for the ‘selective’ plasma membrane permeability of early apoptotic cells to
specific dyes3. Collectively, these data identify PANX1 as a plasma membrane channel mediating
the regulated release of find-me signals and selective plasma membrane permeability during
apoptosis, and a new mechanism of PANX1 activation by caspases.
Previous studies have shown that ATP and UTP are released from intact apoptotic cells,
with no gross leakage of cellular contents2,4. We initially considered three potential
mechanisms for regulated nucleotide release from early-stage apoptotic cells: exocytosis,
blebbing or passage via a plasma membrane channel. Treatment of cells undergoing
apoptosis with the drug brefeldin A (blocking exocytosis5) or Y27632 (inhibiting the Rho
kinase ROCK critical for membrane blebbing6,7) did not affect ATP release (data not
shown). Therefore, we focused on potential channel(s) that might mediate nucleotide release
during apoptosis.
Among the channels suggested to conduct ATP across the plasma membrane are the
connexin and pannexin family channels8–10. Connexins form gap junctions between cells,
mediating intercellular communication8,10, whereas pannexin channels are thought to
function primarily in conducting intracellular molecules to the extracellular space8,9.
Initially, we used pharmacological inhibitors known to inhibit these channels11. The gap
junction inhibitors 18-alpha-glycyrrhetinic acid (18AGA) and flufenamic acid (FFA) had no
detectable effect on apoptosis-induced ATP release (Supplementary Fig. 1a); however, these
drugs were effective in blocking connexin-mediated intercellular communication in a HeLa-
cell-based scrape assay (Supplementary Fig. 1b). The inhibitor carbenoxolone (CBX), which
targets connexin and pannexin channels, inhibited ATP release during apoptosis
(Supplementary Fig. 1a). Interference by CBX in the ATP quantification assay was ruled out
(Supplementary Fig. 2a), and CBX blocked ATP release at all time points assessed, ruling
out changes in the kinetics of release (Fig. 1a). Although CBX-mediated inhibition of ATP
release was comparable to that seen with zVAD(OMe)-fmk (zVAD; cell-permeable pan-
caspase inhibitor that blocks apoptosis and ATP release from apoptotic cells2), CBX did not
inhibit apoptosis, based on caspase activation12 and ‘eat-me’ signal exposure
(Supplementary Fig. 2b, c). CBX also inhibited UTP release after apoptosis induction
(Supplementary Fig. 4a), and the ability of apoptotic cell supernatants to attract THP-1
monocytes (Supplementary Fig. 4b, c). The higher CBX concentration needed for maximum
inhibition of ATP release from apoptotic cells (>100 μM) is likely due to binding of CBX by
albumin (BSA) in the medium, as lower CBX concentrations were sufficient in lower BSA
concentrations (Supplementary Fig. 3a, b). Probenecid, an inhibitor considered more
specific for pannexins over connexins13, also blocked ATP release from apoptotic cells (Fig.
1a). While drug studies have their limitations, the profile of inhibition (sensitivity to CBX
and probenecid, but not 18AGA and FFA), suggested a role for pannexin channels11,14,
which we pursued further.
Among the three pannexins in humans (pannexin 1, 2 and 3)15,16, pannexin 1 (PANX1) was
the most abundant in the human Jurkat T cells used above (Fig. 1b). siRNA-mediated
knockdown of PANX1, followed by induction of apoptosis reduced ATP and UTP release
compared to control (47% and 68% decrease in ATP and UTP, respectively; Fig. 1c–e and
Supplementary Fig. 5a, b). The residual ATP release was likely due to incomplete
knockdown of PANX1 (Fig. 1c and Supplementary Fig. 5a), and was inhibitable by CBX
and zVAD (Supplementary Fig. 5c). Importantly, no morphological differences were seen
between control- and PANX1-siRNA-transfected cells at the time of apoptosis induction
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(data not shown). Total cellular ATP content was also comparable (Supplementary Fig. 5e),
ruling this out as a cause for reduced ATP release. PANX1 knockdown had no effect on
apoptosis progression, assessed by apoptotic caspase activity and by annexin V staining
(Fig. 1d and Supplementary Fig. 5d). Consistent with decreased nucleotide find-me signal
release, apoptotic cell supernatants from PANX1-siRNA-transfected cells also recruited
fewer monocytes in vitro (Fig. 1f). To address chemotactic activity in vivo, we used the
dorsal air pouch model that we had used previously2; cell supernatants were injected into a
sterile air pouch, and leukocytes attracted to the pouch were analysed after 24 h (Fig. 1g).
Supernatants from apoptotic PANX1 knockdown cells recruited fewer leukocytes into the
pouch than supernatants from control-siRNA-transfected cells (Fig. 1g). Collectively, the
PANX1 knockdown studies and pharmacological inhibition by CBX and probenecid
supported a role for PANX1 in the release of the find-me signals ATP and UTP from
apoptotic cells.
We also generated Jurkat cells stably overexpressing Flag-tagged, full-length PANX1 (426
amino acids11; denoted PANX1–Flag) (Fig. 2a). Compared to control-vector-transfected
cells, PANX1–Flag cells released more ATP and UTP upon induction of apoptosis (Fig. 2b,
c), and their apoptotic cell supernatants recruited more monocytes (Fig. 2d). Even with
overexpression of PANX1, the enhanced release of nucleotides was still regulated by the
induction of apoptosis and sensitive to zVAD and CBX (Fig. 2b and data not shown). Thus,
both siRNA-mediated knockdown of PANX1 (‘loss of function’) and overexpression of
PANX1 (‘gain of function’) directly correlate with apoptosis-induced nucleotide release and
find-me-signal-mediated monocyte recruitment.
PANX1 can conduct molecules up to 1 kDa in size across the plasma membrane (ATP and
UTP are 507 and 484 daltons, respectively)8,9, including the monomeric cyanine dye YO-
PRO-1 (ref. 17). Monomeric cyanine dyes are marketed as apoptotic cell indicators, but the
mechanism by which apoptotic cells take up these dyes is not known3. We asked whether
PANX1 mediates the entry of the dyes YO-PRO-1 and TO-PRO-3 (629 and 671 daltons,
respectively) during apoptosis. Interestingly, the uptake of YO-PRO-1 and TO-PRO-3 by
apoptotic Jurkat cells was largely PANX1-dependent. This PANX1-dependent membrane
permeability was selective, as these early-apoptotic cells did not take up the dye propidium
iodide (which marks necrotic cells; data not shown). PANX1 knockdown (Fig. 2e) and
treatment with CBX (Supplementary Fig. 6a) significantly reduced YO-PRO-1 uptake,
whereas transient overexpression of PANX1 enhanced TO-PRO-3 uptake (Supplementary
Fig. 6b). These data suggest an essential role for PANX1 in the release of the find-me
signals ATP and UTP, and in the selective plasma membrane permeability that has long
been considered a hallmark of early-stage apoptotic cells3.
We demonstrated previously that apoptotic primary thymocytes release nucleotide find-me
signals, which is critical for proper phagocytic clearance of dying thymocytes in vivo2.
Therefore, we asked whether thymocytes depend on PANX1 for increased plasma
membrane permeability during apoptosis. Apoptotic thymocytes took up YO-PRO-1, and
treatment with CBX blocked this uptake (similar to the caspase inhibitor zVAD) (Fig. 2f).
However, unlike zVAD, CBX did not inhibit apoptosis, assessed by phosphatidylserine
exposure (Fig. 2f).
We next asked whether apoptosis-induced membrane permeability could be directly
correlated with PANX1-dependent plasma membrane currents. We measured channel
activity at the single-cell level via whole-cell patch-clamp18,19, and made several striking
observations. First, CBX-sensitive currents were detected only in apoptotic cells. In bulk
suspension, where cells undergo apoptosis at different rates20, PANX1 currents were only
detectable in cells that were beginning to bleb (a morphological characteristic of apoptosis;
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denoted ‘dying’ cells), but not in cells that appeared ‘live’ (Fig. 3a–c). Second, the
apoptosis-induced currents were unaffected by 100 μM FFA, but were rapidly inhibited by
100 μM CBX (Fig. 3b, d and Supplementary Figs 7a, b and 8a–d). This rapid inhibition of
the current flux (Fig. 3b and Supplementary Fig. 8d) suggested that CBX acts directly on the
channel responsible for the increased membrane permeability. Third, apoptosis-induced
currents were much larger in cells stably over-expressing PANX1–Flag (Fig. 3c) and
markedly reduced in cells with PANX1 knockdown (Fig. 3e). Importantly, aside from the
magnitude, the voltage-dependent properties of the apoptosis-induced CBX-sensitive current
were essentially identical in control cells, PANX1–Flag overexpressing cells, and PANX1
knockdown cells (Fig. 3d and Supplementary Fig. 8c). Moreover, the IC50 values for CBX
and probenecid, using wild-type Jurkat cells, roughly correspond to concentrations
published in the literature (Supplementary Fig. 9)11. Collectively, these patch-clamp studies
demonstrate that, at the single-cell level, the magnitude of the membrane permeability
induced during apoptosis strongly correlates with the level of PANX1 expression.
We next investigated apoptosis-induced, post-translational modification(s) of PANX1 that
might regulate channel activity. Interestingly, detection of endogenous PANX1 in apoptotic
Jurkat cells by immunoblotting decreased in a time-dependent manner, temporally
correlating with procaspase 3 activation (Fig. 4a). The caspase inhibitor zVAD ‘restored’ the
PANX1 band, whereas CBX did not (although both zVAD and CBX inhibit the apoptosis-
induced nucleotide release) (Fig. 4a and Supplementary Fig. 10a). Loss of Panx1
immunoreactivity, and its restoration by zVAD, was also observed in apoptotic primary
murine thymocytes (Fig. 4b). This suggested an intriguing possibility that PANX1 itself
might be a target of caspase-mediated cleavage. Although another type of modification
could have caused the loss of immunoreactivity to this carboxy-terminal antibody21 (CT Ab;
Fig. 4c), this was ruled out by identical results seen in PANX1–Flag over-expressing cells
using anti-Flag antibody for detection (Supplementary Fig. 10b).
To test whether PANX1 might be a direct target of caspases, we performed an in vitro
cleavage assay by mixing purified active caspases with immunoprecipitated PANX1–Flag
protein. Of those caspases tested, caspases 3 and 7 displayed the most significant cleavage
of PANX1–Flag (Fig. 4d), resulting in loss of PANX1 immunoreactivity. This was not due
to random activity of these caspases, as another C-terminally Flag-tagged protein, ELMO1–
Flag, was not cleaved in the same assay (Supplementary Fig. 10c). Caspase cleavage sites
are typically tetrapeptide sequences ending in an aspartic acid, after which the cleavage
occurs22. Using the online tool CASVM23, we identified two potential caspase cleavage
sites in human PANX1: DMRD in the intracellular loop (residues 164–167; denoted site A)
and DVVD in the C-terminal tail (residues 376–379; denoted site B) (Fig. 4c). To detect
directly the C-terminal cleavage product of PANX1 in apoptotic cells, we established Jurkat
cells stably expressing PANX1 with a C-terminal green fluorescent protein (GFP) tag.
Induction of apoptosis in PANX1–GFP-expressing cells resulted in a cleavage product that
suggested cleavage at site B (Fig. 4e). We then mutated sites A and B (individually and
together) by substituting an alanine for the aspartic acid residues (see Methods) and
performed caspase cleavage reactions. Detection of cleavage products via two different
antibodies (to the second extra-cellular loop (EL2) and to the C-terminal Flag tag) (Fig. 4f
and Supplementary Fig. 10c) showed that site A and site B are indeed two target sites for
caspases 3 and 7 in vitro.
To test the functional relevance of these PANX1 caspase cleavage sites in cells during
apoptosis, we transiently co-transfected Jurkat cells with plasmids coding for wild-type or
mutant PANX1 proteins and the fluorescent protein mCherry (marker for transfection).
After inducing apoptosis, we assessed YO-PRO-1 uptake by mCherry+ cells using flow
cytometry (Fig. 5a). PANX1–Flag expression resulted in higher YO-PRO-1 uptake than the
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control Flag vector. Expression of the PANX1 site A mutant led to the same level of
increased YO-PRO-1 uptake as the wild-type-PANX1-transfected cells, suggesting that site
A is dispensable for PANX1 function under these conditions (Fig. 5a). However, cells
expressing the PANX1 site B mutant showed a dramatic reduction in YO-PRO-1 uptake,
suggesting a dominant-negative effect on YO-PRO-1 uptake by apoptotic cells (YO-PRO-1
mean fluorescence intensities of 1,393 in the site B mutant condition, versus 11,179 in the
control-vector-transfected cells) (Fig. 5a). Because PANX1 is thought to function as an
oligomer24, perhaps a certain number of subunits within the complex have to be cleaved for
channel activation, resulting in a dominant-negative effect due to the presence of subunits
that cannot be cleaved. It is notable that PANX1-site-B-mutant-expressing cells did undergo
apoptosis (annexin-V-positive). Mutation of the aspartic acid residues to glutamic acid
residues (denoted site B EE) replicated the findings with the alanine substitutions, ruling out
charge alterations as a cause (Supplementary Fig. 11a). To assess the effect of the PANX1
site B mutant on plasma membrane currents, we transiently co-transfected Jurkat cells with
plasmids for a fluorescent marker and the various PANX1 constructs. Marker-positive and
dying cells (actively blebbing) revealed a dramatic inhibition of apoptosis-induced, CBX-
sensitive current in the PANX1-site-B-mutant-expressing cells (Fig. 5b). We also
established Jurkat cells stably expressing the PANX1 site B mutant. Upon apoptosis
induction, ATP release and TO-PRO-3 uptake were drastically reduced (Fig. 5c, d),
although the cells became apoptotic (annexin-V-positive) (Fig. 5d). These data suggest that
the caspase cleavage site in the C terminus of PANX1 (site B) is necessary for the induction
of PANX1-mediated plasma membrane permeability during apoptosis.
We next asked whether a PANX1 protein engineered to mimic truncation at site B (see
Methods) would result in basal/constitutive plasma membrane permeability. Transient
expression of the PANX1 truncation mutant led to TO-PRO-3 and YO-PRO-1 uptake by
approximately one-third of the transfected cells (Fig. 5e and data not shown). We also
detected PANX1 currents on cells expressing the truncation mutant that appeared ‘live’ (not
blebbing), suggesting that the currents were due to expression of a constitutively open
channel (Fig. 5f). The current–voltage relationship for the truncation mutant resembles that
of an activated wild-type PANX1 channel, and the currents were CBX-sensitive (Fig. 5f and
Supplementary Fig. 11b). Interestingly, the PANX1 currents were only seen in cells that
were brightest for the co-transfected GFP marker, suggesting that only cells expressing
higher amounts of the truncated/activated subunits form active channels. We performed the
truncation mutant studies 16 h post-transfection, as these cells began to die 24–48 h post-
transfection, perhaps due to continued release of ATP (data not shown). These data identify
that cleavage of PANX1 at site B is necessary and sufficient to activate the channel, defining
a new mechanism for regulation of pannexin channels.
Collectively, these data provide several new insights. This work identifies a new
physiological function for PANX1, demonstrating an essential and non-redundant role in
nucleotide/find-me signal release from apoptotic cells. These data have implications for how
apoptotic cells may modify their extracellular microenvironment through the selective
release of molecules25,26. PANX1 also contributes significantly to plasma membrane
permeability during apoptosis, which is relevant for ‘selective’ dye uptake by early apoptotic
cells. There are still limited examples where caspase-mediated cleavage of specific proteins
during apoptosis subsequently translates to biologically relevant functions27,28. Our work
uncovers a novel caspase-mediated mechanism of PANX1 activation during apoptosis.
Since cleavage site B is evolutionarily conserved among PANX1 homologues (human, mice
and zebrafish), this may be a conserved mechanism of PANX1 regulation during apoptosis.
Since ATP released by dying tumour cells can activate NLRP3/inflammasome-dependent
signalling and promote anti-tumour immunity4, defining a role for PANX1 in ATP release
could also have implications for targeting these channels in cancer therapies.
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Jurkat cells resuspended in serum-free media (RPMI/1% BSA) were treated with 250 ng
ml−1 anti-Fas (CH11 clone) or 100 mJ cm−2 ultraviolet C irradiation (Stratalinker). Primary
murine thymocytes were treated with cross-linked anti-Fas (5 μg ml−1 anti-Fas (Jo2 clone) +
2 μg ml−1 protein G).
Preparation of cell supernatants and nucleotide measurement
Cells were incubated for indicated times after receiving treatments. Supernatants were
collected by two consecutive centrifugations (425g for 2 min at room temperature). ATP
was measured using a luciferase/luciferin assay (CellTiter-Glo; Promega) according to
manufacturer’s instructions. UTP concentrations were quantified by the UDP-glucose
pyrophosphorylase-based reaction, as described previously29.
Migration assay
Transwell migration assays were performed by applying THP-1 cells to the insert and the
chemoattractant in the well of a 24-well plate with 5-μm pore Transwells (Corning) for 1 h
at 37 °C. Supernatants were diluted in some cases to bring the chemotactic activity into the
linear range of the migration assay, with the same dilution applied to all samples in each
experiment. Percentage of input cells that migrated to the lower chamber was determined by
flow cytometry using AccuCount beads (Spherotech).
PANX1 constructs
Human PANX1–Flag construct was generated by PCR cloning of PANX1 cDNA (Open
Biosystems; catalogue number MHS1010-58324) into pEBB-Flag vector. Cleavage site
mutations were performed using a QuikChange mutagenesis kit (Stratagene). PANX1
truncation mutant (amino acids 1–371) was produced by PCR to end at amino acid 371,
immediately followed by a Flag tag (DYKDDDDK), resulting in a 379 amino acid protein
(size that would be produced by caspase cleavage after the last aspartic acid residue in site
B).
Patch-clamp analysis
Whole-cell recordings were obtained at room temperature using patch pipettes (3–5 MΩ)
filled with a Cs-based internal solution. Peak current (at +90 mV) was normalized to cell
capacitance. CBX-sensitive current was taken as the difference in peak current before and
after CBX application.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Release of find-me signals by apoptotic cells is pannexin-1-dependent
a, Time course of ATP release from apoptotic Jurkat cells in the presence of 500 μM
carbenoxolone (CBX) or 2 mM probenecid (Prob). n = 3. No Tx, no treatment. b, mRNA
levels for PANX1, PANX2 and PANX3 in Jurkat cells determined by qPCR, normalized to
PANX1. n = 2. c, PANX1 protein expression in Jurkat cells transfected with control or
PANX1 siRNA. Glycosylated PANX1 (upper band; arrow) was quantified. d, e, PANX1
knockdown does not affect the progression of apoptosis (assessed by apoptotic caspase
activity) (d, n = 3), but decreases ATP (e, n = 10) and UTP (e, n = 3) release 4 h after
apoptosis induction. *, P < 10−5; **, P < 0.01. f, Transwell migration of THP-1 monocytes
towards apoptotic cell supernatants from PANX1-siRNA-treated cells (4 h after ultraviolet
(UV) treatment). *, P < 0.05. Representative of four independent experiments. g, Left,
Schematic of mouse air pouch model for monitoring chemotactic activity of apoptotic cell
supernatants in vivo. Right, CD45+ leukocytes migrating into the pouch were determined
after injecting apoptotic cell supernatants from siRNA-transfected cells. n = 9–10 mice per
group. *, P < 0.05, by ANOVA with Bonferroni post-analysis. Error bars, s.e.m., except in
b, f, where they represent s.d.
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Figure 2. Pannexin 1 expression level correlates with find-me signal release and membrane
permeability
a, Immunoblotting of lysates from control or PANX1–Flag Jurkat cells. b, ATP release by
Jurkat cells after induction of Fas-mediated apoptosis, and 4 h after UV-induced apoptosis. n
= 2. c, UTP levels in supernatants of Jurkat cells 2 h after apoptosis induction. n = 4. d,
Migration of THP-1 monocytes to supernatants from control and PANX1–Flag expressing
cells, collected 2 h after induction of apoptosis. *, P < 0.05. Representative of four
experiments. e, Left, flow cytometry histograms showing YO-PRO-1 dye uptake by control
versus PANX1-siRNA-transfected Jurkat cells with or without apoptosis induction. Right,
uptake of YO-PRO-1 presented as mean fluorescence intensity (MFI) of the entire cell
population. *, P < 0.0005, n = 3. f, Left, YO-PRO-1 uptake by primary murine thymocytes
undergoing anti-Fas-induced apoptosis, with zVAD or CBX treatments. Right, percentage of
apoptotic cells (annexin V positive and propidium iodide negative). n = 2. Error bars
represent s.d., except in c (s.e.m.).
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Figure 3. Carbenoxolone-sensitive current induced during apoptosis is pannexin-1-dependent
a, Morphology of anti-Fas treated Jurkat cells used to identify ‘live’ and ‘dying’ cells (based
on blebbing). b, Patch-clamp recordings from Jurkat cells, receiving indicated treatments.
Peak whole-cell current (at +90 mV) is shown under conditions when bath solution was
perfused with FFA (100 μM, blue shading) or CBX (100 μM, pink shading). Exemplar
traces are representative of 5–15 cells per group. c, CBX-sensitive current density in
indicated Jurkat cells, normalized to whole-cell capacitance (pA/pF). *, P < 0.01. n ≥ 7 per
group. d, Current–voltage relationships of apoptosis-induced current in dying Jurkat cells
(from b), with current measured over a range of voltages (only dying cells shown, as live
cells have very little current). Note different y axes. Traces representative of 4–15 cells. e,
CBX-sensitive current density in PANX1-siRNA-transfected cells induced to undergo
apoptosis. *, P < 0.05. n ≥ 8 per group. All error bars represent s.e.m.
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Figure 4. Pannexin 1 is a target of effector caspase cleavage during apoptosis
a, b, Fas-mediated apoptosis results in loss of PANX1 detection with antibody targeted to
PANX1 C terminus in Jurkat cells (a) and primary murine thymocytes (b). c, Schematic of
PANX1–Flag protein indicating the predicted caspase cleavage sites (sites A and B) and the
epitopes recognized by the EL2 (extracellular loop 2) and C-terminal antibodies. The
predicted products of caspase cleavage at sites A and B are also shown. d, In vitro cleavage
of immunoprecipitated PANX1–Flag incubated with the indicated purified active caspases.
Loss of immunoreactivity to Flag assessed. Representative of two independent experiments.
e, Jurkat cells stably expressing a C-terminally GFP-tagged PANX1 were induced to
undergo apoptosis and assessed for the cleaved C-terminal fragment (which runs at ~33
kDa). Representative of two independent experiments. f, In vitro cleavage of indicated
PANX1–Flag proteins (wild type and caspase cleavage site mutants), incubated with the
indicated caspases.
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Figure 5. Caspase-mediated cleavage of pannexin 1 results in channel activation during
apoptosis
a, b, Jurkat cells transiently transfected with indicated constructs were assessed for YO-
PRO-1 uptake (a) and current density (b) 48 h post-transfection. The MFI for YO-PRO-1
uptake by the gated population is shown (a) and the analysis of dying cells in b was
performed as in Fig. 3. *, P < 0.01, n ≥ 5 for each group. c,d, Jurkat cells stably transfected
with the indicated plasmids were assessed for ATP release (c, n = 3), TO-PRO-3 uptake (d,
left) and annexin V staining (d, right) 2 h after induction of apoptosis. MFI for the TO-
PRO-3 positive peaks and percentage of annexin V positive cells are shown. n = 3. e, TO-
PRO-3 uptake by Jurkat cells 16 h after transient transfection with full-length or truncated
PANX1. Schematic of full-length and truncated PANX1 (amino acids 1–426 and 1–371,
respectively) are shown. n = 3. f, CBX-sensitive currents in Jurkat cells transiently
transfected with indicated PANX1 proteins (full length or truncation mutant). Patch-clamp
was performed on cells that appeared morphologically healthy. n ≥ 5 per group. Error bars
and ± represent s.e.m.
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